新辅助治疗后靶淋巴结标记技术:AXSANA/EUBREAST-03/AGO-B-053研究
该研究基于AXSANA前瞻性多中心队列,纳入2596例新辅助化疗前标记靶淋巴结并完成手术的初诊淋巴结阳性乳腺癌患者,评估不同标记方法的检出与切除率。结果显示探针引导可检测标记物(放射性粒子、磁种子、雷达标记、RFID)的靶淋巴结检出率最高(96.6%),优于碳墨(94.9%)和夹子(89.6%)(P < .001)。
要点
- 探针引导标记物靶淋巴结检出率96.6%,高于夹子89.6%(P < .001)。
- 夹子是最常用标记(77.2%),磁种子11.1%,碳墨7.4%。
- 91.2%计划靶向切除的患者成功检出并切除靶淋巴结。
核心结论
- 新辅助化疗前使用探针引导可检测标记物标记转移淋巴结,其靶淋巴结检出率优于夹子和碳墨。
研究设计与样本
- AXSANA(EUBREAST-03)前瞻性多中心队列研究,截至2025年1月6日纳入26个国家6129例患者,其中2596例有新辅助化疗前靶淋巴结标记并完成手术。
主要发现
- 2596例患者中,13.3%诊断时≥4枚可疑淋巴结。
- 新辅助化疗前标记方法:夹子2003例(77.2%)、磁种子287例(11.1%)、碳墨192例(7.4%)、雷达标记119例(4.6%)、放射性粒子18例(0.7%)、RFID 12例(0.5%)、其他2例(0.1%)。
- 标记1枚靶淋巴结2427例(93.5%),2枚138例(5.3%),≥3枚27例(1%)。
- 计划靶向切除2100例(80.9%),其中靶向腋窝清扫2076例(80.0%),靶淋巴结活检24例(0.9%)。
- 靶淋巴结检出并切除1915例(91.2%);探针引导标记物检出率96.6%(放射性粒子100%、磁种子96.9%、雷达标记96.1%、RFID 90%),碳墨94.9%,夹子89.6%(P < .001)。
临床怎么用
- 对新辅助化疗后转阴的淋巴结阳性乳腺癌,优先选择探针引导可检测标记物标记靶淋巴结以提高检出率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surgical axillary staging in patients with node-positive breast cancer (BC) who converted to clinical node negativity through neoadjuvant chemotherapy (NACT) has changed significantly in recent years. Targeted axillary dissection (TAD) and target lymph node (TLN) biopsy (TLNB) became increasingly popular. However, data comparing marking techniques for the TLN are limited. Here, we evaluate marking techniques in the largest prospective cohort worldwide. MATERIALS AND METHODS: Among patients from the ongoing prospective multicenter AXSANA (EUBREAST-03) study who received TLN marking and TAD/TLNB, we evaluated different marking methods with respect to detection and removal rates and clinical performance. RESULTS: Until January 6, 2025, 6,129 patients from 26 countries were enrolled. Of these patients, 2,596 had ≥1 TLN marked before NACT and completed surgery; 13.3% of the patients had ≥4 suspicious nodes at diagnosis. Pre-NACT TLN marking used a clip in 2,003 patients (77.2%), magnetic seed in 287 (11.1%), carbon ink in 192 (7.4%), radar marker in 119 (4.6%), radioactive seed in 18 (0.7%), radiofrequency identification device (RFID) in 12 (0.5%), or other methods in two (0.1%). One TLN was marked in 2,427 patients (93.5%), two TLNs in 138 (5.3%), and ≥3 in 27 patients (1%). Targeted removal of the TLN was planned in 2,100 patients (80.9%; TAD in 2,076 [80.0%] and TLNB in 24 [0.9%]). The TLN was detected and removed by TAD/TLNB in 1,915 patients (91.2%). TLN detection rate was the highest in patients whose TLNs were marked pre-NACT with markers suitable for probe-guided detection (96.6%; radioactive seed: 100%, magnetic seed: 96.9%, radar marker: 96.1%, RFID: 90%), followed by carbon ink (94.9%) and clip (89.6%; P < .001). CONCLUSION: This large prospective analysis of patients with initially clinically node-positive BC receiving NACT demonstrates that probe-guided detection markers used to mark metastatic nodes before NACT provide superior detection rates.
引用
- Banys-Paluchowski M, Hartmann S, de Boniface J, et al. Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. J Clin Oncol. 2026. PMID: 41564379. doi:10.1200/JCO-25-01921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。